Back

Single-cell RNA-seq and V(D)J profiling of immune cells in COVID-19 patients

Fan, X.; Chi, X.; Ma, W.; Zhong, S.; Dong, Y.; Zhou, W.; Ding, W.; Fan, H.; Yin, C.; Zuo, Z.; Yang, Y.; Zhang, M.; Ma, Q.; Liu, J.; Fang, T.; Wu, Q.; Chen, W.; Wang, X.

2020-05-27 infectious diseases
10.1101/2020.05.24.20101238 medRxiv
Show abstract

Coronavirus disease 2019 (COVID-19) has caused over 220,000 deaths so far and is still an ongoing global health problem. However, the immunopathological changes of key types of immune cells during and after virus infection remain unclear. Here, we enriched CD3+ and CD19+ lymphocytes from peripheral blood mononuclear cells of COVID-19 patients (severe patients and recovered patients at early or late stages) and healthy people (SARS-CoV-2 negative) and revealed transcriptional profiles and changes in these lymphocytes by comprehensive single-cell transcriptome and V(D)J recombination analyses. We found that although the T lymphocytes were decreased in the blood of patients with virus infection, the remaining T cells still highly expressed inflammatory genes and persisted for a while after recovery in patients. We also observed the potential transition from effector CD8 T cells to central memory T cells in recovered patients at the late stage. Among B lymphocytes, we analyzed the expansion trajectory of a subtype of plasma cells in severe COVID-19 patients and traced the source as atypical memory B cells (AMBCs). Additional BCR and TCR analyses revealed a high level of clonal expansion in patients with severe COVID-19, especially of B lymphocytes, and the clonally expanded B cells highly expressed genes related to inflammatory responses and lymphocyte activation. V-J gene usage and clonal types of higher frequency in COVID-19 patients were also summarized. Taken together, our results provide crucial insights into the immune response against patients with severe COVID-19 and recovered patients and valuable information for the development of vaccines and therapeutic strategies.

Matching journals

The top 2 journals account for 50% of the predicted probability mass.

1
Cell Discovery
54 papers in training set
Top 0.1%
47.0%
2
Protein & Cell
25 papers in training set
Top 0.2%
8.3%
50% of probability mass above
3
Cellular & Molecular Immunology
14 papers in training set
Top 0.2%
6.2%
4
Journal of Molecular Cell Biology
21 papers in training set
Top 0.1%
4.1%
5
Genomics, Proteomics & Bioinformatics
171 papers in training set
Top 2%
3.9%
6
Science China Life Sciences
26 papers in training set
Top 0.4%
3.2%
7
Signal Transduction and Targeted Therapy
29 papers in training set
Top 0.4%
3.0%
8
iScience
1063 papers in training set
Top 9%
2.3%
9
Cell Research
49 papers in training set
Top 0.8%
2.0%
10
eLife
5422 papers in training set
Top 39%
1.9%
11
Cell Reports
1338 papers in training set
Top 25%
1.7%
12
Nature Communications
4913 papers in training set
Top 53%
1.7%
13
National Science Review
22 papers in training set
Top 1%
1.1%
14
Journal of Genetics and Genomics
36 papers in training set
Top 2%
0.9%
15
Cell
370 papers in training set
Top 15%
0.9%
16
Clinical and Translational Medicine
30 papers in training set
Top 0.9%
0.8%
17
Frontiers in Immunology
586 papers in training set
Top 7%
0.8%
18
Frontiers in Genetics
197 papers in training set
Top 10%
0.7%
19
mBio
750 papers in training set
Top 11%
0.7%
20
Human Molecular Genetics
130 papers in training set
Top 4%
0.7%
21
Life Science Alliance
263 papers in training set
Top 2%
0.7%
22
Genome Medicine
154 papers in training set
Top 9%
0.7%
23
Communications Biology
886 papers in training set
Top 27%
0.7%
24
The Journal of Immunology
146 papers in training set
Top 2%
0.7%
25
GigaScience
172 papers in training set
Top 4%
0.6%